Lynne Sullivan - Nov 18, 2022 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Role
CFO & Head of Corp. Dev.
Signature
/s/ Alexander Nguyen, Attorney-in-Fact for Lynne Marie Sullivan
Stock symbol
UBX
Transactions as of
Nov 18, 2022
Transactions value $
$6,373
Form type
4
Date filed
11/21/2022, 04:26 PM
Previous filing
Jun 14, 2022
Next filing
Dec 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UBX Common Stock, $0.0001 par value Other $6.37K +925 +2.88% $6.89 33K May 15, 2022 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UBX Stock Option (Right to Buy) Award $0 +80K $0.00 80K Nov 18, 2022 Common Stock 80K $2.38 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan (the ESPP). The acquisition of those 925 shares was also exempt pursuant to Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 15, 2022.
F3 Includes RSUs which vest over time measured from the grant date.
F4 Reflects a 1-for-10 reverse stock split of the Issuer's common stock, effected by the Issuer on October 19, 2022, which was exempt from reporting pursuant to Rule 16a-9.
F5 The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on February 18, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date.